Related Experiment Videos
Choline magnesium trisalicylate does not impair platelet aggregation
Pharmatherapeutica
|January 1, 1981
Summary
Choline magnesium trisalicylate, used long-term by arthritis patients, did not significantly affect blood platelet aggregation. This finding supports its safety profile, showing no interference with normal blood clotting mechanisms.
Area of Science:
- Pharmacology
- Hematology
- Rheumatology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) can affect platelet function.
- Choline magnesium trisalicylate is an NSAID used for arthritis.
- Understanding its impact on platelet aggregation is crucial for patient safety.
Purpose of the Study:
- To evaluate the effect of chronic choline magnesium trisalicylate use on blood platelet aggregation.
- To determine if this salicylate formulation interferes with platelet response to common agonists.
Main Methods:
- Assessed platelet aggregation in nine arthritis patients on long-term choline magnesium trisalicylate therapy.
- Stimulated platelet aggregation using adenosine diphosphate (ADP), epinephrine, and collagen.
- Excluded one patient due to suspected aspirin ingestion.
Main Results:
- Platelet aggregation was normal in 5 patients.
- Three patients showed minimal reduction in ADP-induced aggregation, with unclear causes.
- One patient exhibited atypical aggregation patterns, likely due to confounding aspirin use.
Conclusions:
- Prolonged use of choline magnesium trisalicylate does not appear to interfere with platelet aggregation.
- Results align with previous findings of minimal gastrointestinal bleeding risk with this drug.